Newsroom
Strive to Deliver Breakthroughs
-
March 12, 2025
Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies
Cambridge, MA, Rotterdam, NL, Shanghai, CN – March 12, 2025 - Élancé Therapeutics aims to improve current obesi...
View more -
March 11, 2025
Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal
Cambridge, MA, Rotterdam, NL, Shanghai, CN — March 10, 2025 Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to th...
View more -
March 11, 2025
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer
Cambridge, MA, Rotterdam, NL, Shanghai, CN — March 10, 2025 Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to th...
View more -
February 26, 2025
HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies
Cambridge, MA, Rotterdam, NL, Shanghai, CN – February 25, 2025 HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company inc...
View more -
February 20, 2025
Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development
Cambridge, MA, Rotterdam, NL, Shanghai, CN — February 20, 2025 Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceut...
View more -
February 14, 2025
Harbour BioMed Announces Business Progress and Update
Cambridge, MA, Rotterdam, NL, Shanghai, CN – February 13, 2025 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceu...
View more -
February 05, 2025
Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
Cambridge, MA, Rotterdam, NL, Shanghai, CN — February 4, 2025 Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceuti...
View more -
January 10, 2025
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
Cambridge, MA, Rotterdam, NL, Shanghai, CN — January 10, 2025 Harbour BioMed (HKEX: 02142, the “Company”), a global biophar...
View more -
November 15, 2024
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer
Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 14, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceuti...
View more -
November 08, 2024
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
Cambridge, MA, Rotterdam, NL, Suzhou, CN – November 8, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutic...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1